Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IFN beta-ring FCB
- Development stage
- Preclinical
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
IFN beta-ring FCB is a preclinical-stage recombinant interferon beta (IFN-β) candidate being developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba. The drug is designed for the treatment of multiple sclerosis, leveraging the immunomodulatory properties of type I interferons to manage neuroinflammation and reduce the frequency of relapses. The "ring" designation in its name likely refers to a circularized protein structure, a modification intended to enhance the molecule's stability and resistance to proteolytic degradation. The "FCB" suffix is a common designation in CIGB's pipeline for specific biopharmaceutical projects, potentially indicating a fusion protein or a specific formulation. As an agonist of the interferon-alpha/beta receptor (IFNAR), IFN beta-ring FCB aims to modulate cytokine production, decrease pro-inflammatory mediators, and inhibit the migration of inflammatory cells across the blood-brain barrier.
- Other names
- IFN-beta-ring FCB
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on IFN beta-ring FCB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFN beta-ring FCB.